Impact of genetic markers on treatment of non-small cell lung cancer.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Advances in Experimental Medicine and Biology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/978-1-4614-6176-0_6PMID 23288638
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comprehensive genomic characterization of squamous cell carcinoma of the lung.

  2012cited by this paper
• Cancer statistics, 2012

  2012cited by this paper
• LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

  2012cited by this paper
• Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

  2012cited by this paper
• EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study.

  2012cited by this paper
• ROS1 rearrangements define a unique molecular class of lung cancers.

  2012cited by this paper
• Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial.

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

  2012cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.

  2012cited by this paper
• Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005.

  2011cited by this paper
• Global cancer statistics

  2011cited by this paper
• Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

  2011cited by this paper
• Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

  2011cited by this paper
• Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

  2011cited by this paper
• Impact of crizotinib on survival in patients with advanced, ALK-positive NSCLC compared with historical controls.

  2011cited by this paper
• An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).

  2011cited by this paper
• Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.

  2011cited by this paper
• Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

  2011cited by this paper
• Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC).

  2011cited by this paper
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

  2011cited by this paper
• Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC.

  2011cited by this paper
• Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC).

  2011cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents

  2010cited by this paper
• Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.

  2010cited by this paper
• Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• F1000 highlights

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• Cancer Statistics, 2010

  2010cited by this paper
• Cell culture modeling of genotype-directed sensitivity to selective kinase inhibitors: targeting the anaplastic lymphoma kinase (ALK).

  2009cited by this paper
• Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

  2009cited by this paper
• F1000 highlights

  2009cited by this paper
• Colorectal hepatic metastases: adjuvant chemotherapy and survival.

  2009cited by this paper
• A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC).

  2009cited by this paper
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

  2009cited by this paper
• Phase I dose escalation trial (ARQ 197-111) evaluating combination of selective c-Met inhibitor ARQ 197 and erlotinib.

  2009cited by this paper
• Gastrosplenic fistula from Hodgkin's lymphoma.

  2009cited by this paper
• Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066.

  2009cited by this paper
• A mouse model for EML4-ALK-positive lung cancer

  2008cited by this paper
• The Met tyrosine kinase receptor in development and cancer

  2008cited by this paper
• Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.

  2008cited by this paper
• Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.

  2008cited by this paper
• Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

  2008cited by this paper
• The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

  2008cited by this paper
• BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

  2008cited by this paper
• Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

  2008cited by this paper
• VEGF polymorphisms and survival in early-stage non-small-cell lung cancer.

  2008cited by this paper
• MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

  2007cited by this paper
• Immunostimulatory monoclonal antibodies for cancer therapy

  2007cited by this paper
• Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.

  2007cited by this paper
• Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.

  2007cited by this paper
• Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

  2007cited by this paper
• Randomized Phase II Study of Gemcitabine Plus Cisplatin or Carboplatin, With or Without Cetuximab, As First-Line Therapy for Patients With Advanced or Metastatic Non–Small-Cell Lung Cancer

  2007cited by this paper
• Epidermal growth factor receptor mutations in lung cancer

  2007cited by this paper
• Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

  2007cited by this paper
• ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice.

  2006cited by this paper
• Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21.

  2006cited by this paper
• Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.

  2006cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers

  2005cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

  2005cited by this paper
• Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer.

  2005cited by this paper
• Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.

  2004cited by this paper
• Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

  2004cited by this paper
• Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

  2004cited by this paper
• Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

  2004cited by this paper
• Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

  2003cited by this paper
• Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21)

  2003cited by this paper
• Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

  2003cited by this paper
• High pre‐treatment serum level of vascular endothelial growth factor (VEGF) is associated with poor outcome in small‐cell lung cancer

  1998cited by this paper
• Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells.

  1989cited by this paper

• Quantification and analyses of seven tyrosine kinase inhibitors targeting hepatocellular carcinoma in human plasma by QuEChERS and UPLC-MS/MS.

  2024cites this paper
• LncRNA AWPPH accelerates the progression of non-small cell lung cancer by sponging miRNA-204 to upregulate CDK6.

  2020cites this paper
• Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies

  2016cites this paper
• Preanalytical variables and phosphoepitope expression in FFPE tissue: quantitative epitope assessment after variable cold ischemic time

  2015cites this paper
• Chapter 15 – Cancer Chemoprevention

  2015cites this paper
• The Cytokine Profile and Prostate Specific Antigen Levels in Prostate Cancer Patients at Kenyatta National Hospital

  2015cites this paper
• Discovering cancer biomarkers from clinical samples by protein microarrays

  2015cites this paper
• DGIdb 2.0: mining clinically relevant drug–gene interactions

  2015cites this paper
• Molecular markers for targeted neoadjuvant rectal cancer therapy

  2013cites this paper